97 related articles for article (PubMed ID: 19902676)
1. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
Lilue M; Palacios S
Ginecol Obstet Mex; 2009 Oct; 77(10):475-81. PubMed ID: 19902676
[TBL] [Abstract][Full Text] [Related]
2. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU
Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
Perry R; Cassagnol M
Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
6. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
[TBL] [Abstract][Full Text] [Related]
7. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
Cheng RJ; Dupont C; Archer DF; Bao W; Racketa J; Constantine G; Pickar JH
Climacteric; 2013 Feb; 16(1):17-27. PubMed ID: 22646219
[TBL] [Abstract][Full Text] [Related]
8. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
[TBL] [Abstract][Full Text] [Related]
10. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
Gallagher JC; Strzinek RA; Cheng RF; Ausmanas MK; Astl D; Seljan P
J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
[TBL] [Abstract][Full Text] [Related]
11. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
Kamath J; Handratta V
Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
[TBL] [Abstract][Full Text] [Related]
12. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.
Berhan Y; Berhan A
Ethiop J Health Sci; 2014 Jul; 24(3):209-18. PubMed ID: 25183927
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine: another "me too" drug?
Sopko MA; Ehret MJ; Grgas M
Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.
Umland EM; Falconieri L
Int J Womens Health; 2012; 4():305-19. PubMed ID: 22870045
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
16. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
[TBL] [Abstract][Full Text] [Related]
17. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
18. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
Aziz MT; Good BL; Lowe DK
Ann Pharmacother; 2014 May; 48(5):626-32. PubMed ID: 24577146
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
Handley AP; Williams M
J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
Archer DF; Pinkerton JV; Guico-Pabia CJ; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):47-56. PubMed ID: 23266840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
